Contact
searchSearch
HMP Global
Login

November 2016

Feature
Lessons From Change Management Theory for the Implementation of Clinical Pathways
11/15/2016
Tobias Romeyke, PhD; Elisabeth Nöhammer, DHSc; Harald Stummer, PhD
Performance-based models for health care reimbursement are designed to promote and reward an efficient allocation of resources as well as to ensure quality.1 One such model is based on adherence to predetermined...
Performance-based models for health care reimbursement are designed to promote and reward an efficient allocation of resources as well as to ensure quality.1 One such model is based on adherence to predetermined...
...
11/15/2016
Journal of Clinical Pathways
Feature
Defining Target Populations for Clinical Pathways
11/15/2016
David Hughes, BSN
A critical consideration in pathway development is identification of the target population for the pathway. A pathway is often developed for a specific population of patients with a given clinical diagnosis....
A critical consideration in pathway development is identification of the target population for the pathway. A pathway is often developed for a specific population of patients with a given clinical diagnosis....
A...
11/15/2016
Journal of Clinical Pathways

Column

Clinical Pathways GPS
Sites of Care: An Opportunity to Address Efficiency and Effectiveness in Clinical Pathways
11/15/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
As our health system increases the financial responsibility of health care providers, there is increased focus among these providers on reducing costs. Part of this cost-reduction effort involves improving the...
As our health system increases the financial responsibility of health care providers, there is increased focus among these providers on reducing costs. Part of this cost-reduction effort involves improving the...
As...
11/15/2016
Journal of Clinical Pathways
Pharma Insights
Creating Room to Show Value of New Products When Good Enough Treatments Exist
11/15/2016
Dan Renick, RPh; Larry Blandford, PharmD
Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to...
Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to...
...
11/15/2016
Journal of Clinical Pathways

Insights

Interview
ACS CAN Addresses Controversy Surrounding Opioids
11/15/2016
Mark Fleury, PhD, MS
An interview with Mark Fleury, PhD, MS, principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network, Washington, DC.  Pain as a result of cancer or...
An interview with Mark Fleury, PhD, MS, principal, Policy Development, Emerging Science, American Cancer Society Cancer Action Network, Washington, DC.  Pain as a result of cancer or...
...
11/15/2016
Journal of Clinical Pathways
Interview
Making Decisions About New Cancer Treatments With Limited Evidence
11/15/2016
Jim C. Hu, MD, MPH
An interview with Jim C Hu, MD, MPH, urologic oncologist and director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian and Weill Cornell Medicine, New York,...
An interview with Jim C Hu, MD, MPH, urologic oncologist and director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian and Weill Cornell Medicine, New York,...
...
11/15/2016
Journal of Clinical Pathways

Department

Research in Review
Review Examines Prognostic Value of Tumor-Infiltrating Lymphocytes in Early Breast Cancer
11/15/2016
Tumor-infiltrating lymphocytes (TILs) have been described in various tumors, including breast cancer. In early breast cancer, the presence of TILs is associated with better outcomes and response to therapy. A...
Tumor-infiltrating lymphocytes (TILs) have been described in various tumors, including breast cancer. In early breast cancer, the presence of TILs is associated with better outcomes and response to therapy. A...
...
11/15/2016
Journal of Clinical Pathways
Research in Review
Analysis Finds Tocilizumab Superior to Conventional DMARDs in RA
11/15/2016
A comparative effectiveness analysis of biologics for rheumatoid arthritis (RA) showed that tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional disease-modifying antirheumatic...
A comparative effectiveness analysis of biologics for rheumatoid arthritis (RA) showed that tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional disease-modifying antirheumatic...
A...
11/15/2016
Journal of Clinical Pathways
Research in Review
Chest Pain Clinical Pathway in Pediatric ED Can Influence Resource Use
11/15/2016
Because most young children are not able to accurately describe or localize their pain, ruling out cardiac disease in children can be challenging, leading to increased health care utilization for chest pain...
Because most young children are not able to accurately describe or localize their pain, ruling out cardiac disease in children can be challenging, leading to increased health care utilization for chest pain...
...
11/15/2016
Journal of Clinical Pathways
Research in Review
Pediatric Stroke Pathway Improves Time to Definitive Diagnosis
11/15/2016
A pediatric stroke clinical pathway significantly improved time to definitive diagnosis while also streamlining the care provided to children presenting to the pediatric emergency department (ED) with focal...
A pediatric stroke clinical pathway significantly improved time to definitive diagnosis while also streamlining the care provided to children presenting to the pediatric emergency department (ED) with focal...
A...
11/15/2016
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

November 2016 Volume 2

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use